COVID-19 SARS-CoV-2 preprints from medRxiv and bioRxiv

31,637 Articles (22,913 medRxiv, 8,724 bioRxiv)

Most recent first Previous |  Page 1613: Articles 16121-16130  | Next

Prophylactic protection against respiratory viruses conferred by a prototype live attenuated influenza virus vaccine.
Rathnasinghe, R., Salvatore, M., Zheng, H., Jangra, S., Kehrer, T., Mena, I., Schotsaert, M., Muster, T., Palese, P., Garcia-Sastre, A.
10.1101/2021.04.28.441797 — Posted: 2021-04-28
Nucleic acid delivery of immune-focused SARS-CoV-2 nanoparticles drive rapid and potent immunogenicity capable of single-dose protection
Konrath, K., Liaw, K., Wu, Y., Zhu, X., Walker, S., Xu, Z., Schultheis, K., Chokkalingam, N., Tursi, N. J., Du, J., Sullivan, M., Purwar, M., Moore, A., Machado, V., Maricic, I., Reuschel, E., Frase, D., Iffland, C., Broderick, K., Humeau, L., Smith, T., Pallesen, J., Weiner, D. B., Kulp, D. W.
10.1101/2021.04.28.441474 — Posted: 2021-04-28
Regulation of Lysosome-Associated Membrane Protein 3 (LAMP3) in Lung Epithelial Cells by Coronaviruses (SARS-CoV-1/2) and Type I Interferon Signaling
Chilakamarti, R.
10.1101/2021.04.28.441840 — Posted: 2021-04-28
Recombination patterns in coronaviruses
Müller, N. F., Kistler, K., Bedford, T.
10.1101/2021.04.28.441806 — Posted: 2021-04-28
A spike-ferritin nanoparticle vaccine induces robust innate immune activity and drives polyfunctional SARS-CoV-2-specific T cells
Carmen, J. M., Shrivastava, S., Lu, Z., Anderson, A., Morrison, E. B., Sankhala, R. S., Chen, W.-H., Chang, W. C., Bolton, J., Matyas, G. R., Michael, N. L., Joyce, M. G., Modjarrad, K., Currier, J. R., Bergmann-Leitner, E., Malloy, A. M. W., Rao, M.
10.1101/2021.04.28.441763 — Posted: 2021-04-28
SARS-COV-2 induced Diarrhea is inflammatory, Ca2+ Dependent and involves activation of calcium activated Cl channels
Donowitz, M., Tse, C.-M., Dokladny, K., Rawat, M., Hurwitz, I., Ye, C., Kell, A., Lin, R., Lee, S., Guo, C. G., Tsai, S. J., Cox, A., Gould, S., In, J., Bradfute, S. B., Zachos, N., Kovbasnjuk, O.
10.1101/2021.04.27.441695 — Posted: 2021-04-28
Massively Multiplexed Affinity Characterization of Therapeutic Antibodies Against SARS-CoV-2 Variants
Engelhart, E., Lopez, R., Emerson, R., Lin, C., Shikany, C., Guion, D., Kelley, M., Younger, D.
10.1101/2021.04.27.440939 — Posted: 2021-04-28
Therapeutic effect of CT-P59 against SARS-CoV-2 South African variant
Lee, S.-Y., Ryu, D.-K., Choi, Y. K., Moore, P., Baalen, C. A. v., song, r., Tijsma, A. S., Gwete-Moyo, T., Kim, M., Kim, Y.-I., Kim, C., Kim, J.-I., Kwon, K.-S.
10.1101/2021.04.27.441707 — Posted: 2021-04-28
A broadly neutralizing antibody protects against SARS-CoV, pre-emergent bat CoVs, and SARS-CoV-2 variants in mice
Martinez, D., Schaefer, A., Gobeil, S., Li, D., De la Cruz, G., Parks, R., Lu, X., Barr, M., Manne, K., Mansouri, K., Edwards, R. J., Yount, B., Anasti, K., Montgomery, S., Shen, X., Zhou, T., Kwong, P., Graham, B., Mascola, J. R., Montefiori, D., Alam, M., Sempowski, G., Wiehe, K., Saunders, K. O., Acharya, P., Haynes, B., Baric, R. S.
10.1101/2021.04.27.441655 — Posted: 2021-04-28
Ethnic differences in SARS-CoV-2 vaccine hesitancy in United Kingdom healthcare workers: Results from the UK-REACH prospective nationwide cohort study
Woolf, K., McManus, I. C., Martin, C. A., Nellums, L. B., Guyatt, A. L., Melbourne, C., Bryant, L., Gogoi, M., Wobi, F., Al-Oraibi, A., Hassan, O. B., Gupta, A., John, C., Tobin, M. D., Carr, S., Simpson, S., Gregary, B., Aujayeb, A., Zingwe, S., Reza, R., Gray, L. J., Khunti, K., Pareek, M., UK-REACH Study Collaborative Group
10.1101/2021.04.26.21255788 — Posted: 2021-04-28

RSS  Collection RSS | JSON

The feeds linked above output metadata for the 100 most recent papers in the collection.To access the metadata for the entire collection in JSON or XML, visit the collection API.

Subject Areas
* The Clinical Trials and Epidemiology subject categories are now closed to new submissions following the completion of bioRxiv's clinical research pilot project and launch of the dedicated health sciences server medRxiv (submit.medrxiv.org). New papers that report results of Clinical Trials must now be submitted to medRxiv. Most new Epidemiology papers also should be submitted to medRxiv, but if a paper contains no health-related information, authors may choose to submit it to another bioRxiv subject category (e.g., Genetics or Microbiology).